HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Impact of CFTR-modulating drugs on GH-IGF-1 axis impairment in adult patients with cystic fibrosis.

AbstractINTRODUCTION:
A new class of drugs in the treatment of cystic fibrosis (CF) includes two agents: lumacaftor, which corrects CFTR channel protein, and ivacaftor, which increases CFTR channel activity. In our previous study we recruited 50 stable adults with CF and 16 of them showed growth hormone deficit (GHD): 7 patients severe and 9 patients partial GHD.
MATERIAL AND METHODS:
We decided to re-evaluate ten patients with the GHRH + arginine test of whom only five were treated with lumacaftor/ivacaftor.
RESULTS:
All CF patients in therapy with lumacaftor/ivacaftor showed a marked improvement in GHD. Two patients moved from a severe GHD to a normal response to the GH/IGF-1 axis test, and three patients who had partial GHD moved to normal response.
CONCLUSION:
The pituitary gland may be damaged by CF disease and could benefit of the action of correcting drugs.
AuthorsC Pascucci, R V De Biase, D Savi, S Quattrucci, L Gnessi, C Lubrano, A Lenzi
JournalJournal of endocrinological investigation (J Endocrinol Invest) Vol. 42 Issue 11 Pg. 1361-1363 (Nov 2019) ISSN: 1720-8386 [Electronic] Italy
PMID31006073 (Publication Type: Journal Article)
Chemical References
  • Aminophenols
  • Aminopyridines
  • Benzodioxoles
  • CFTR protein, human
  • Drug Combinations
  • IGF1 protein, human
  • Quinolones
  • lumacaftor, ivacaftor drug combination
  • Human Growth Hormone
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • Insulin-Like Growth Factor I
Topics
  • Adult
  • Aminophenols (therapeutic use)
  • Aminopyridines (therapeutic use)
  • Benzodioxoles (therapeutic use)
  • Cystic Fibrosis (drug therapy, genetics, pathology)
  • Cystic Fibrosis Transmembrane Conductance Regulator (genetics)
  • Drug Combinations
  • Female
  • Follow-Up Studies
  • Growth Disorders (pathology, prevention & control)
  • Human Growth Hormone (metabolism)
  • Humans
  • Insulin-Like Growth Factor I (metabolism)
  • Male
  • Middle Aged
  • Mutation
  • Prognosis
  • Quinolones (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: